Yahoo
NasdaqGS - Nasdaq Real Time Price USD

GoodRx Holdings, Inc. (GDRX)

3.4900 -0.0500 (-1.41%)
At close: October 30 at 4:00:01 PM EDT
3.3959 -0.0941 (-2.70%)
After hours: October 30 at 7:17:29 PM EDT
Trade GDRX on Coinbase
Chart Range Bar
Loading chart for GDRX
  • Previous Close 3.5400
  • Open 3.5200
  • Bid 2.5300 x 200
  • Ask 4.4000 x 200
  • Day's Range 3.4000 - 3.5358
  • 52 Week Range 1.7700 - 3.8900
  • Volume 1,507,157
  • Avg. Volume 1,287,164
  • Market Cap (intraday) 1.191B
  • Beta (5Y Monthly) 1.69
  • PE Ratio (TTM) 69.80
  • EPS (TTM) 0.0500
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 3.95
  • Motley Fool Rating Bearish

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

www.goodrx.com

697

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GDRX
28.78%
S&P 500 (^GSPC)
10.73%

1-Year Return

GDRX
1.45%
S&P 500 (^GSPC)
11.11%

3-Year Return

GDRX
31.84%
S&P 500 (^GSPC)
81.91%

5-Year Return

GDRX
92.17%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 200.41M
Earnings 8.54M
Profit Margin 4.26%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
200M
1.0%
2.0%
3.0%
4.0%

Analyst Insights

View More

Analyst Price Targets

2.65 Low
3.95 Average
3.4900 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/21/2026
Analyst Barclays
Rating Action Maintains
Rating Underweight
Price Action Raises
Price Target 3 -> 4

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.07%

  • Return on Assets (ttm)

    3.05%

  • Return on Equity (ttm)

    2.52%

  • Revenue (ttm)

    785.23M

  • Net Income Avi to Common (ttm)

    16.25M

  • Diluted EPS (ttm)

    0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    296.11M

  • Total Debt/Equity (mrq)

    83.22%

  • Levered Free Cash Flow (ttm)

    112.5M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: